Retatrutide remains under clinical investigation and has not yet received regulatory approval, with ongoing Phase 3 trials evaluating long-term safety and effectiveness
This variability highlights that individual experiences differ widelypotentially due to biological differences, dosages, weight-loss rates , personal expectations, mental health, lifestyle factors, relationship dynamics, and other medications
Obesity (Silver Spring) (2010) 18:7807
TrkB expression is higher in iSPNs than their counterpart, dSPNs 49 , indicating their higher vulnerability to TrkB signalling alteration
Tier 2: lifestyle modifications that reduce reflux by 40 to 60% Beyond diet, specific behavioral changes significantly reduce reflux frequency and severity